{"id":"W4297821381","doi":"10.1016/j.annonc.2022.07.1945","title":"1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Merck Sharp and Dohme; EMD Serono; Genentech; Unicancer; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Pfizer; Incyte; Ipsen; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; American Society of Clinical Oncology; Boston Scientific Corporation; Invitae; AstraZeneca; Advanced Accelerator Applications; Endocyte; Teva Pharmaceutical Industries; Merck; Yuhan; Gilead Sciences; Exelixis; Sanofi; Amgen","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Interim analysis; Biomarker; Randomization; Progression-free survival; Prednisone; Oncology; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002163504,0.0008854188,0.00148776,0.000615821,0.0002879306,0.001791014,0.0005662777,0.0006111896,0.004885083],"category_scores_gemma":[0.00266862,0.0003232343,0.001873519,0.001283367,0.0003174507,0.0007800987,0.0004955624,0.001224535,0.0008608124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007891806,"about_ca_system_score_gemma":0.001543488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001648292,"about_ca_topic_score_gemma":0.005731154,"domain_scores_codex":[0.9991499,0.0003383334,0.00006048757,0.0001230582,0.0002024951,0.0001256621],"domain_scores_gemma":[0.9984992,0.0004040929,0.0005203894,0.0001101689,0.0002245618,0.0002415486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.544479,0.002522166,0.09977616,0.002693168,0.01703984,0.0003939459,0.0001418652,0.002702716,0.02083521,0.0006003373,0.031038,0.2777776],"study_design_scores_gemma":[0.2296304,0.06350669,0.5599024,0.0006744761,0.03517543,0.001870744,0.0002156127,0.002195138,0.01180302,0.001981191,0.09279018,0.0002547799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8965149,0.03854592,0.001746219,0.004079132,0.001121422,0.001110609,0.04432824,0.0002990558,0.01225442],"genre_scores_gemma":[0.9198724,0.00840247,0.003546444,0.003334617,0.0008053522,0.0008110906,0.05652415,0.00009664369,0.00660683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004885083,"threshold_uncertainty_score":0.01634222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09282910501671691,"score_gpt":0.408646793756521,"score_spread":0.3158176887398041,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}